'India, China Hold Key to Drug Firms' Global Expansion' (Asia)
This article was originally published in PharmAsia News
Executive Summary
Global pharmaceutical companies will have to expand into China and India to compete in the expanding world pharmaceutical market, concludes the new pharmaceutical report "Pharma 2020" by PricewaterhouseCoopers. Companies need to begin testing drugs with human patients earlier in the developmental process, says Pharma 2020, to avoid failure during expensive late-stage clinical trials. In the year 2020, China will be either the second or third largest pharmaceutical market in the world, predicts the report. In addition, up to 20 percent of all worldwide drugs sales will occur in the developing countries of Brazil, China, India, Indonesia, Mexico, Russia, and Turkey. The report predicts that the global pharmaceutical market will total $1.3 trillion in 2020. The most competitive companies will be focusing on many lower-cost medicines, rather than on billion-dollar blockbuster drugs. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.